9,445 Shares in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Acquired by SG Americas Securities LLC

SG Americas Securities LLC purchased a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 9,445 shares of the specialty pharmaceutical company's stock, valued at approximately $1,173,000.

Other large investors also recently bought and sold shares of the company. GAMMA Investing LLC boosted its stake in shares of Jazz Pharmaceuticals by 63.7% in the first quarter. GAMMA Investing LLC now owns 1,015 shares of the specialty pharmaceutical company's stock valued at $126,000 after purchasing an additional 395 shares during the period. Range Financial Group LLC acquired a new position in Jazz Pharmaceuticals in the 1st quarter worth $917,000. First Citizens Bank & Trust Co. purchased a new position in Jazz Pharmaceuticals in the 1st quarter valued at about $318,000. UMB Bank n.a. grew its stake in shares of Jazz Pharmaceuticals by 116.4% during the first quarter. UMB Bank n.a. now owns 673 shares of the specialty pharmaceutical company's stock valued at $84,000 after acquiring an additional 362 shares in the last quarter. Finally, Radnor Capital Management LLC grew its stake in shares of Jazz Pharmaceuticals by 7.8% during the first quarter. Radnor Capital Management LLC now owns 8,540 shares of the specialty pharmaceutical company's stock valued at $1,060,000 after acquiring an additional 615 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Insider Activity at Jazz Pharmaceuticals

In related news, Director Seamus Mulligan acquired 1,621 shares of the business's stock in a transaction that occurred on Monday, May 12th. The shares were acquired at an average cost of $103.00 per share, for a total transaction of $166,963.00. Following the completion of the purchase, the director now directly owns 101,621 shares in the company, valued at $10,466,963. This trade represents a 1.62% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Bruce C. Cozadd sold 500 shares of the company's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $107.90, for a total transaction of $53,950.00. Following the completion of the sale, the chief executive officer now directly owns 438,473 shares of the company's stock, valued at $47,311,236.70. The trade was a 0.11% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,000 shares of company stock worth $355,925 in the last ninety days. 4.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on JAZZ shares. Needham & Company LLC reissued a "buy" rating and issued a $202.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, June 11th. Morgan Stanley reduced their target price on Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. Piper Sandler restated an "overweight" rating and issued a $147.00 price target (down previously from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and increased their price objective for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. Finally, Barclays reissued an "overweight" rating and set a $200.00 price objective (up from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $184.00.

Jazz Pharmaceuticals Stock Performance

JAZZ stock traded down $0.59 during midday trading on Friday, reaching $107.65. The company had a trading volume of 335,987 shares, compared to its average volume of 1,031,182. The firm has a market capitalization of $6.51 billion, a PE ratio of 14.36, a P/E/G ratio of 4.67 and a beta of 0.33. The stock has a 50 day moving average price of $108.00 and a 200 day moving average price of $120.18. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $148.06. The company has a quick ratio of 2.97, a current ratio of 3.38 and a debt-to-equity ratio of 1.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). The company had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.86% and a return on equity of 26.62%. The company's revenue for the quarter was down .5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.68 EPS. Analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.